Giving you the flexibility to fit your processing conditions to better meet your needs
Whole blood
Leukodepletion is a major step to improve transfusion safety thanks to a significant reduction of patient adverse reactions and pathogen transmissions.
Macopharma develops and manufactures leukodepletion systems to improve the quality and the safety of blood components, allowing better patient outcome.
Leucoflex LXT enables the filtration up to 500 mL of whole blood stored
at room temperature within 24 hours of collection
FQE system with LXT filter for leucoreduced plasma and leucoreduced Red Blood Cells concentrate preparation
Leucoflex MTL1 enables the filtration up to 500 mL of whole blood stored at room temperature
within 24 hours of collection, or up to 72 hours when stored at 4°C.
DQE system with MTL1 filter for leucoreduced plasma and leucoreduced Red Blood Cells concentrate preparation
Benefits
High leukodepletion performance
- Leucoflex LXT provides high performance far below the European requirement of < 1 x 106 WBC/unit
- Leucoflex MTL1 provides reliable performance below the AABB requirement of < 5 x 106 WBC/unit
High blood component recovery > 90%
Features
Design allowing visual monitoring during filtration
Fast filtration process
Quality
Leucoflex MTL1 and LXT filters are used in more than 25 countries worldwide.
Macopharma is a major global player in the filtration of blood components, with unique know-how and expertise. We have a deep understanding of your requirements and strive to provide you with reliable and robust filters, guaranteeing high performance stability and reproducibility
This information is for exclusive use of healthcare professionals.
The products are not available in every country, please contact your sales representative.
MACOPHARMA • Rue Lorthiois 59240 Mouvaux France • Tel : + 33 (0) 3 20 11 84 00 • Fax : +33 (0) 3 20 11 84 03
Société par actions simplifiée au Capital de 493.115 € RCS Lille Metropole 391 600 905 • Code APE 4641 Z • TVA FR 313 916 009 05